Stocks · News reference
Filed: 2026-11-06 AccNo: 0001437749-26-035576 Size: 164 KB Item 7.01: Regulation FD Disclosure
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
U.S. Senators have launched an inquiry into Molina Healthcare and other major insurers regarding their cooperation with the Trump administration in terminating Affordable Care Act (ACA) coverage for 760,000 enrollees.
Oscar Health is diversifying revenue streams beyond ACA insurance through Lucie, an enhanced direct enrollment platform targeting a $650+ billion marketplace, and CHOICE, which capitalizes on growing ICHRA adoption. While the company has gained 116.1% year-to-date, its stock trades at a premium valuation (P/E of 14.17 vs. industry average of 9.02) with consensus estimates showing projected revenue and earnings decreases for 2026-2027.
Molina Healthcare reaffirmed its full-year 2026 adjusted earnings guidance of at least $5.25 per share on its Q3 earnings call. The company is seeing state Medicaid reimbursement rates align with elevated care costs, signaling a potential trough in margins and the beginning of a multiyear recovery cycle. Management expects $4 per share in embedded earnings from contract backlogs in 2027, including a $6 billion Florida specialized children's health program, with state work requirement implementations showing moderate member attrition.
J.P. Morgan analyst John Stansel has maintained a hold rating on Molina Healthcare, Inc. while increasing the stock's price target from $220 to $225.
Deutsche Bank has increased its price target for Molina Healthcare, Inc. from $147 to $163.